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Background and Aim: Treating severe alcoholic hepatitis involves the 
exposure of patients to corticosteroids for 7 days to assess ‘response’. The 
aim of this study was to assess the prognostic and therapeutic implications of 
baseline Neutrophil-to-Lymphocyte ratio (NLR) in patients with severe 
alcoholic hepatitis. 
Methods: NLR was derived retrospectively from STOPAH patients and an 
independent validation group. Area under the Receiver Operating Curve 
(AUC) analysis was performed. Kaplan-Meier analysis was used to assess 
survival. Log-Rank test and Odds Ratio (OR) were used for comparative 
analysis. 
Results: Baseline NLR was available for 789 STOPAH patients. The AUC for 
NLR was modest for 90-day outcome (0.660), but it was associated with 
infection, acute kidney injury (AKI) and severity of alcoholic hepatitis. 90-day 
survival was not affected by prednisolone treatment with NLR<5 but mortality 
was reduced with prednisolone treatment when NLR 5-8: 21.0% cf. 34.5%; 
p=0.012. prednisolone treatment increased the chance of Lille response if the 
NLR≥5 (56.5% cf. 41.1%: p=0.01; OR 1.86) but increased the risk of Day 7 
infection (17.3% cf. 7.4%: p=0.006; OR 2.60) and AKI (20.8% cf. 7.0%: 
p=0.008; OR 3.46) if NLR>8. Incorporation of NLR into a modified Glasgow 
Alcoholic Hepatitis Score (mGAHS) improved the AUC to 0.783 and 0.739 for 
28-day and 90-day outcome respectively. 
Conclusion: The NLR is associated with AKI and infection in severe alcoholic 
hepatitis. The NLR identifies those most likely to benefit from corticosteroids 
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at baseline (NLR 5-8). The mGAHS has a good predictive value for 28- and 
90-day outcomes. 




Treatment for severe alcoholic hepatitis remains problematic. Whilst 
corticosteroids appear to have a favourable effect upon short-term (28-day) 
mortality, this advantage is not sustained to 90 days or beyond1,2. 
Corticosteroid treatment is also associated with a higher risk of infection2. 
Therefore, not all patients with alcoholic hepatitis benefit from such an 
approach. The difficulty is in identifying those for whom such treatment is 
useful, but avoiding unnecessary exposure to corticosteroids for those whom 
such treatment is ineffective or even detrimental. Various strategies have 
been suggested. A recommended approach is to treat alcoholic hepatitis 
patients but to assess ‘response’ after 7 days of therapy, often using the Lille 
score3. An unfavourable response would indicate an early discontinuation of 
corticosteroids, thereby limiting treatment exposure. It has been suggested 
that Lille score ‘response’ at Day 4 may be indicative of an early response and 
so further curtail corticosteroid exposure4. A more recent strategy has been to 
only treat those with more severe disease as indicated by high MELD, ABIC 
(Age, Bilirubin, INR, Creatinine score) or GAHS (Glasgow Alcoholic Hepatitis 
Score) values, so limiting the number of patients treated5. However even with 
this approach, benefit beyond 28 days is only seen in those with a Day 7 
response. Thus current treatment strategies rely upon exposure to potentially 
ineffective, or even harmful, corticosteroid therapy. The optimal approach 
would be to identify patients at baseline for whom corticosteroid treatment 
would be beneficial. 
Recently several studies have found a high Neutrophil-to-Lymphocyte Ratio 
(NLR) to be indicative of a worse prognosis in a variety of different liver 
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disease contexts: patients on the liver transplant waiting list6, those with low 
MELD scores7, hospitalised patients with cirrhosis8, patients with acute-on-
chronic liver failure (ACLF)9 and patients with decompensated liver disease 
without ACLF10. The prognostic value of NLR in these studies appears 
additional to standard scores of liver function and to that of total white blood 
cell count (WCC) alone. Relative lymphopenia plays an important role as well 
as an inflammatory neutrophilia; lymphopenia along with an increased 
CD4+/CD8+ ratio has been noted in alcohol-related liver disease previously11. 
The aim of this study was to assess whether baseline NLR might be used to 
identify steroid responders among a cohort of patients with severe alcoholic 
hepatitis. 





Patients recruited to the STOPAH trial were studied. The characteristics of 
these patients have been described in detail previously12. Inclusion was based 
upon a clinical diagnosis of severe alcoholic hepatitis with recent onset of 
jaundice (serum bilirubin>80µmol/l) and heavy alcohol misuse and no other 
aetiology of liver disease. All patients had a baseline Discriminant Function 
(DF) greater than or equal to 32. Patients were randomised by a factorial 
design to receive prednisolone and placebo, pentoxifylline and placebo, 
prednisolone and pentoxifylline or double placebo. The overall STOPAH 
results showed no therapeutic effect with pentoxifylline at any time point and 
so patients randomised to pentoxifylline were analysed as per untreated 
(placebo) patients. Thus, the therapeutic comparison was for those treated 
with prednisolone or not given at a dose of 40mg per day for 4 weeks. 
Analysis was performed on an intention to treat basis. As data on blood 
lymphocyte count was not collected in the original STOPAH dataset, this 
information was obtained retrospectively in order to calculate the NLR. The 
trial was approved by the Multicentre Research Ethics Committee 
(09/MRE09/59) and under the oversight of University of Southampton Clinical 
Trials Unit. All participants, or their legally appointed representative, provided 
written informed consent. 
Mortality at 28 and 90 days after randomisation was analysed. Outcome 
beyond 90 days was not assessed as other factors, such as continued alcohol 
use, were felt to influence outcome beyond that point. Patients were 
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consented for follow-up using the National Health Service data linkage service 
so that even if lost to direct follow-up their outcomes could be captured. 
Baseline Acute Kidney Injury (AKI) was defined by an initial creatinine 
≥133µmol/l and incident AKI was defined as either an increase of serum 
creatinine by 26.5µmol/l or by 50% by Day 7 in those without baseline AKI. All 
patients were screened for infection and active infections were treated prior to 
participation. A pre-determined analysis excluding those who presented 
initially with either gastro-intestinal bleeding or sepsis was carried out. 
Surveillance for infection continued after randomisation and rates of infection 
noted. MELD (pre-2016 UNOS variant), GAHS and Lille Scores were 
calculated with prognostic thresholds of 21, 9 and 0.45 respectively as 
previously described. The Chronic Liver Failure (CLIF) - Organ Failure and 
CLIF-Consortium ACLF scores and grades were calculated with the limitation 
of the lack of respiratory data managed as previously described13,14. 
Validation Group 
A Validation Group was derived from patients assessed and treated for 
alcoholic hepatitis from four United Kingdom centres outside of the STOPAH 
trial: Leeds, Bristol, Brighton and Plymouth. Data was collected in keeping 
with local Clinical Governance practice. All patients had a serum bilirubin 
greater than 80µmol/l and a DF greater than or equal to 32. Treatment with 
corticosteroids (prednisolone 40mg/day) and their continuation or 
discontinuation in the light of an assessment of response after 7 days was 
based on local clinical discretion. 
Statistical Analyses 
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Analyses were performed using MedCalc Statistical Software version 17.6 
(MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2017). 
Comparison of the discriminatory strength of scores was performed by area 
under the Receiver Operating Curve (AUC) analysis. Optimal cut-offs were 
identified by calculating the Youden Index (J). Kaplan-Meier analysis was 
used to assess survival and survival curves were compared using the Log-
Rank test with Hazard Ratio (HR) described where relevant. Results are 
presented with 95% confidence intervals (95% CI). Direct comparisons 
between data were performed using t-tests and between proportions using 
Odds Ratio (OR) calculation. Pearson’s correlation co-efficient (r) was 
calculated for associations between variables. 





Of the 1103 patients recruited to STOPAH, it proved possible to obtain data to 
calculate the baseline NLR in 789 (71.5%). Of these patients 393 were treated 
with prednisolone. The overall mortality at Day 90 was 25.1% for those 
treated with prednisolone and 25.5% not treated with prednisolone (p=0.682). 
The mean NLR at baseline for all patients was 6.51 (6.14, 6.88). Patient 
characteristics are described in Table 1 with details of the STOPAH patients 
included and excluded from the analysis, and those of the Validation Group. 
All groups were well matched at baseline with the exception of a difference in 
total white blood cell count between the STOPAH patients with NLR values 
and those for whom the lymphocyte count was not available. 
Associations of NLR in Alcoholic Hepatitis 
Severity of alcoholic hepatitis and NLR were related (Supplementary Table 1). 
Survivors at Day 90 had having a lower NLR than those who had died: 5.7 
(5.44, 6.09) cf. 8.70 (7.67, 9.72): p<0.0001. Patients with a low GAHS (less 
than 9) had a mean NLR of 5.05 (4.74, 5.37); those with a high GAHS 
(greater than or equal to 9) had a mean NLR of 8.12 (7.47, 8.77): p<0.0001. 
Similarly a MELD less than 21 was associated with a mean NLR of 4.89 (4.27, 
5.49); MELD greater than or equal to 21 the mean NLR was 6.72 (6.29, 7.14): 
p<0.0001. The NLR correlated with the Lille score (r=0.212 (0.13, 0.29); 
p<0.0001): patients with a favourable Lille Score (<0.45) having a lower NLR 
than those with an unfavourable score (≤0.45): 5.78 (5.33, 6.22) cf. 7.71 
(6.90, 8.53): p<0.001. A higher NLR was associated with higher ACLF grade 
(Supplementary Figure 1). 
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The NLR was significantly greater in those patients who presented with 
infection and in those with AKI at baseline. It was also greater in those who 
developed new infection in the first 7 days and 28 days after randomisation 
(Table 2). There was a strong correlation between the total WCC and NLR: 
r=0.564 (0.52, 0.60); p<0.0001. 
Predictive Discrimination for Mortality of NLR and Outcome of Prednisolone 
Treatment (Figure 1 and Supplementary Table 2) 
Overall the baseline NLR had a modest discriminatory capacity with an AUC 
of 0.660 (0.626, 0.693) with an optimal cut-point of 5 (J=0.247) for 90-day 
mortality. Mortality at Day 90 was 16.1% for those with a NLR<5 and 33.6% 
for those with a NLR≥5 (p<0.0001; HR 2.39 (1.81, 3.15)). With regards to 90-
day outcome, in those patients with a NLR<5 (n=372, 47.1% of the 
population), prednisolone had no effect upon outcome, although there was an 
insignificant trend towards higher mortality with treatment: 19.0% cf. 13.2%; 
p=0.176. 
For those with a NLR≥5 who were treated with prednisolone, the optimal cut-
point was 8 (J=0.272). For these patients, mortality at Day 90 was 21.0% for 
those with a NLR<8 and 41.8% for those with a NLR≥8 (p=0.0003: HR 2.50 
(1.52, 4.12)). The mortality of the 199 patients (25.2%) with a NLR>8 was 
unaffected by prednisolone treatment: 41.8% cf. 37.6%; p=0.604. However, 
for the 218 patients (27.6%) with NLR 5-8, prednisolone treatment was 
associated with a significant reduction in 90-day mortality: 21.0% cf. 34.5%; 
p=0.012; HR 0.52 (0.31, 0.86) (Figure 3). This pattern was repeated with 
exclusion of those who presented initially with either GI bleeding or sepsis. 
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Day 7 Response and Risk of Infection and AKI Relative to NLR Range (Figure 
2) 
For those with an NLR<5, prednisolone treatment did not increase the chance 
of a favourable Lille score: 63.7% cf. 64.5% for those untreated. The 
proportion of patients achieving a favourable Lille score with prednisolone 
treatment was increased for those with an NLR≥5: (56.5% cf. 41.1%: p=0.01; 
OR 1.86 (1.16, 2.99)). NLR≥5 patients were more likely to achieve a 25% fall 
in bilirubin from baseline with prednisolone treatment compared with those not 
treated: 60.8% cf. 27.4% (p<0.0001; OR 2.76 (1.72, 4.43)). This was not so 
for those with NLR<5: 47.8% cf. 40.3% (p=0.243 OR 1.36 (0.81, 2.26)). The 
significance of the Lille score regarding 90-day outcome varied depending 
upon NLR category. Those with an unfavourable Lille score whether they 
received corticosteroids or not and an NLR<5 had a lower mortality (26.2%: 
p=0.0021) compared with NLR 5-8 (46.3%) and NLR>8 (51.9%). prednisolone 
treatment reduced the 90-day mortality of NLR 5-8 patients with a favourable 
Lille score compared with those not treated: 8.9% cf. 25.0%: p=0.046; HR 
0.32 (0.11, 0.97). However even for those with an NLR 5-8 and treated with 
corticosteroid, a Lille non-response was associated with a higher mortality: 
48.2% cf. 8.9%: p=0.0001; HR 6.55 (2.39, 17.98). 
The risk of developing infection within 7 days after prednisolone treatment 
was greater for those with an NLR>8 compared with an NLR<8: 17.3% cf. 
7.4%: p=0.006; OR 2.60 (1.32, 5.14). This difference was also seen with 
incident infections until 28 days after prednisolone treatment: 30.6% cf. 
20.0%: p=0.031; OR 1.76 (1.05, 2.96). For those with an NLR<8, 
prednisolone treatment was associated with a lesser chance of infection by 
NLR and Alcoholic Hepatitis 
13 
 
Day 7 compared with untreated patients (7.4% cf. 18.4%: p=0.013; OR 2.00 
(1.16, 3.46)) but this was not so for those with an NLR>8 (17.3% cf. 13.9%: 
p=0.499; OR 0.77 (0.36, 1.66)). 
Similarly, the risk of developing incident AKI after prednisolone treatment was 
greater for those with a NLR>8 compared with a NLR<8: 20.8% cf. 7.0%: 
p=0.008; OR 3.46 (1.39, 8.62). For those with NLR<8, prednisolone treatment 
was associated with a lesser chance of incident AKI compared with untreated 
patients (7.0% cf. 17.1%: p=0.005; OR 2.72 (1.35, 5.47)) but again this was 
not so for those with NLR>8 (20.8% cf. 20.0%: p=0.913; OR 0.95 (0.38, 
2.39)). 
Incorporation of NLR into GAHS 
In view of the expected correlation of NLR with total WCC, the NLR was 
incorporated into the GAHS with an NLR threshold of 5 replacing the WCC 
threshold of 15, creating a modified GAHS (mGAHS) (Table 3). The AUCs for 
mGAHS for 28-day and 90-day outcomes were 0.783 (0.752, 0.812) and 
0.738 (0.705, 0.769) respectively. For 28-day outcome the mGAHS AUC was 
superior to that of the DF (0.683: p<0.0001; 0.06, 0.14), the original GAHS 
(0.762: p=0.027; 0.002, 0.04), the MELD (0.738: p=0.0013; 0.009, 0.08) and 
the CLIF-OF Score (0.730: p=0.022; 0.007, 0.08) (Figure 3). At a threshold of 
9, the mGAHS had greater sensitivity than the original GAHS (82.3% cf. 
71.2%) but lesser specificity (49.4% cf. 60.8%) for 90-day outcome. The 
corresponding sensitivity and specificity for MELD relative to a threshold of 21 
were 92.4% and 20.0% (Supplementary Table 3). A mGAHS≥9 was present 
in 460 patients (58.6%) with a 90-day mortality of 35.4% compared with a 
mortality of 10.8% for those with mGAHS<9 (p<0.0001 HR 3.91 (2.96, 5.17)) 
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(Supplementary Figure 2). The corresponding figures for the original GAHS 
were 373 patients (47.4%) ≥9 with 90-day mortality of 38.3% compared with a 
mortality of 13.8% for those with GAHS<9 (p<0.0001; HR 3.34 (2.52, 4.42)). 
For MELD, 630 patients (83.6%) had a score ≥21 with 90-day mortality of 
28.4% compared with a mortality of 8.9% for those with MELD<9 (p<0.0001; 
HR 3.66 (2.54, 5.29)). 
The proportions of NLR categories relative to MELD, GAHS and mGAHS 
category are shown in Supplementary Figure 3. Within NLR categories, 
mGAHS did not affect the potential benefit from prednisolone: those with an 
NLR 5-8 showed benefit with prednisolone, and those with NLR<5 or >8 
showed no prednisolone benefit, irrespective of whether the mGAHS was less 
than or greater than 9 (Table 4). 
Validation Group 
There were 237 patients in the validation group, 138 of whom were treated 
with prednisolone. The overall mortality at Day 90 was 26.3% for those 
treated with prednisolone and 32.6% not treated with prednisolone (p=0.20). 
The mean NLR at baseline for all patients was 8.56 (7.23, 9.84). Patient 
characteristics are described in Table 1. 
As with the STOPAH cohort the NLR was greater in those who presented with 
AKI (10.22 cf. 7.37: p=0.014; 0.57, 5.14) and those who presented initially 
with sepsis (10.06 cf. 7.36: p=0.023; 0.38, 5.01).  
NLR Category and Prednisolone Treatment 
There was no reduction in mortality with prednisolone treatment for those with 
NLR<5 or >8 at either 28 days or 90 days. At Day 28 those with NLR 5-8 
treated with prednisolone had a reduced mortality compared with those 
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untreated: 2.7% cf. 28.6%: p=0.0023; HR 0.084 (0.03, 0.27). The trend 
continued to Day 90 but was not significant: 21.6% cf. 37.1%: p=0.097; HR 
0.484 (0.20, 1.14). However, for those with mGAHS≥9 and NLR 5-8 there was 
a reduction in 90-day mortality with prednisolone treatment: 23.3% cf. 46.4%: 
p=0.036; HR 0.268 (0.10, 0.71). (Table 5). There was no evidence of benefit 
for those with NLR<5 or >8 in relation to mGAHS category. 
Performance of mGAHS 
The AUC for 90-day outcome was highest for mGAHS (0.716: 0.652, 0.774) 
compared with the original GAHS (0.698: 0.633, 0.757), DF (0.655: 0.589 
0.717) and MELD (0.702: 0.637, 0.761). At a threshold of 9, the mGAHS had 
almost identical sensitivity (83.4%) and specificity (49.1%) as the STOPAH 
cohort for 90-day outcome. Again, similar to the STOPAH cohort mGAHS≥9 
was present in 144 patients (61.0%) with a 90-day mortality of 39.4% 
compared with 12.0% for those with mGAHS<9 (p<0.0001 HR 3.87 (2.39, 
6.28)). 
Treatment Strategies 
We assessed the effect of different treatment strategies in patients from the 
STOPAH cohort who had NLR available. A comparison of these is shown in 
Table 6. Those approaches which applied a baseline prognostic score to 
determine treatment exposed a greater proportion of patients to prednisolone: 
DF 100%; MELD (threshold of 21) 84%; GAHS (threshold of 9) 47%. Using 
NLR 5-8 to determine those who should have treatment, only 28% of patients 
would have received prednisolone. Despite the reduced number of patients 
exposed to prednisolone treatment, the overall mortality of the NLR strategy 
was less than that of any of the baseline prognostic score strategies. In 
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addition, the rate of reported infection by Day 28 was reduced with the NLR 
strategy compared with any of the baseline score strategies. 




The decision to treat severe alcoholic hepatitis with corticosteroids has been a 
contentious issue for many years. There is some short-term improvement in 
outcome with such treatment when given to patients with a DF greater than 
321,2,15. However this benefit does not extend beyond 28 days and it has not 
been possible to define which of these patients will respond before starting 
treatment. There is also an increased risk of infection with corticosteroid 
treatment potentially limiting any beneficial impact of this therapy16. The 
recommended approach is to look for evidence of response after 4-7 days of 
exposure to corticosteroids and to continue treatment if such a response is 
favourable. This response is usually indicated by a fall in serum bilirubin which 
is incorporated into the Lille score3. A more recent approach to reducing 
corticosteroid exposure is to only treat those with more severe disease as 
indicated by a high GAHS, ABIC or MELD value4,5, however even with this 
targeted approach benefit beyond 28 days depends upon response after 
initiating treatment. The optimal treatment strategy would be to identify those 
likely to benefit from treatment at baseline rather than having to give a trial of 
therapy. Not only would this target those likely to benefit, it would lessen the 
risk to those for whom such treatment could be deleterious. 
Several recent reports suggested means to identify patients who might benefit 
from corticosteroids before such exposure. Higher density of Mallory bodies 
and more severe hepatocyte ballooning on biopsy may be associated with 
non-response17. Alternatively, high circulating levels of bacterial DNA may 
predict the development of infection within the first seven days of 
corticosteroid therapy and identify non-responders16. A further study found 
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that circulating microvesicles, reflective of oxidative stress, are more 
numerous and larger in patients with a Lille non-response18 as are higher 
levels of urinary albumin19. Higher levels of lipopolysaccharide, procalcitonin 
and the presence of the systemic inflammatory response syndrome (SIRS) 
have also been shown to indicate a worse outcome at 90 days in 
corticosteroid treated patients20. Unfortunately it was not possible to calculate 
the SIRS for our patients as the respiratory component was not recorded. 
However the NLR is a simple, readily accessible score that has been applied 
to liver disease previously as prognostic indicator. The current observations 
indicate the NLR has at best modest overall prognostic discrimination in 
alcoholic hepatitis. However, with appropriate calibration it can identify those 
who may benefit from treatment. Those with low (less than 5) or high (greater 
than 8) NLR values do not appear to benefit from prednisolone treatment. 
However, for those with NLR values between 5 and 8, an improvement in 90-
day outcome was observed with corticosteroid treatment. The previously 
observed improvement in 28-day survival for those with high GAHS (greater 
than or equal to 9) is probably explained by the lower number of those with 
NLR<5 in this poor prognostic group. However even this poor prognostic 
group is heterogeneous with regards to NLR categories which may explain 
the failure to predict a favourable outcome with corticosteroids after 28 days. 
The mGAHS has a higher proportion of those with a favourable NLR 5-8 
category for corticosteroid effect when greater than or equal to 9, though the 
predictive capacity of NLR 5-8 was also seen in those with a lower mGAHS. 
Using the NLR to target treatment would substantially reduce those exposed 
to corticosteroids with the expectation of a sustained improvement in outcome 
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for those so treated. It should also be noted that a high Lille score was still 
indicative of worse outcome even for those with NLR 5-8, therefore steroid 
exposure could be curtailed even further for those with an unfavourable Lille 
score. For those with NLRs too low or too high for corticosteroids, the options 
for management are for effective supportive treatments or the investigation of 
alternative or novel approaches.  
The association of NLR with AKI has been noted before with increased values 
found in patients with hepatorenal syndrome and those with refractory 
ascites6,21. Similarly NLR has been associated with risk of infection in patients 
with cirrhosis8 and severity of sepsis in critical care22. It is interesting to note 
that in these studies the prognostic value of NLR appears to be independent 
of standard scores of prognosis in liver disease such as the MELD and Child-
Turcotte-Pugh scores9,23. The degree of neutrophilia may be reflective of the 
degree of inflammation but the relative lymphopenia may reflect a more subtle 
alteration of immune regulation7,10, 24. In addition the degree of lymphopenia 
may also be reflective of sarcopenia as has been noted in other clinical 
contexts25. Protein energy malnutrition is a frequent finding in alcoholic 
hepatitis and is strongly related to outcome26 and sarcopenia is increasingly 
recognised as an important factor in liver disease prognosis independent of 
traditional laboratory-based markers of liver function27. It is possible that the 
NLR is simply another marker of SIRS, and SIRS, especially that associated 
with infection, is an indicator of overall prognosis20. The presence of SIRS on 
admission has also been previously associated with a greater risk of 
developing AKI28,29. In the current study baseline NLR has been shown to be 
reflective of the presence of AKI and infection at presentation, and also 
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predictive of the development of these complications subsequently. However, 
the presence of SIRS has not previously been shown to identify those who will 
most likely benefit from corticosteroid therapy. In the current study the NLR 
provides information relating to therapeutic options as well as prognosis and 
complications. The SIRS criteria are binary, whereas the NLR is a continuous 
measure which may reflect the complex interaction between pro- and anti-
inflammatory factors in alcoholic hepatitis. It may be an indicator of where a 
patient is in the fine balance between inflammatory hepatic injury and the 
development of sepsis and/or multi-organ failure (AKI). Those with NLR less 
than 5 derived no benefit from corticosteroids with no greater chance of a Lille 
response compared with untreated patients. Those with higher NLR were 
more likely to have a Lille response with corticosteroids, but the potential 
benefit of this was offset for those with NLR greater than 8 probably because 
of failure to reduce the chance of developing sepsis and/or AKI. 
The application of the NLR to treatment demonstrated that it could be used to 
target prednisolone treatment more effectively without any compromise in 
overall outcome. The absolute risk of 28-day infection and 90-day mortality 
were actually reduced by a NLR approach. Current guidelines suggest the 
use of a baseline score to determine a trial of prednisolone treatment and 
then use of the Lille Score at Day 7 to identify those whose treatment should 
continue for a further 3 weeks. The European Association for the Study of the 
Liver guidelines suggest a DF greater than or equal to 32 or a GAHS greater 
than or equal to 9 as the threshold for treatment30; the American College of 
Gastroenterology suggest a MELD greater than or equal to 2131. An NLR 
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approach would substantially reduce prednisolone exposure and may reduce 
the 90-day mortality in comparison to these recommendations. 
Incorporation of the NLR into the GAHS instead of the WCC to create the 
mGAHS improved the discriminatory power of the score. However there was 
evidence of benefit from corticosteroids even for those with mGAHS<9 whose 
NLR was 5-8. This suggests that whilst the mGAHS has greater prognostic 
implications, the NLR is more ‘theragnostic’, that is, predictive of therapeutic 
response. Prognosis is important to manage patient expectations and to 
anticipate the course of illness, whereas theragnosis advises the clinician 
towards specific interventions. The Validation Group confirmed the prognostic 
usefulness of the mGAHS as well as identifying the NLR 5-8 group as those 
most likely to benefit from corticosteroid therapy. It is important to note that 
this group validated mGAHS and NLR in severe alcoholic hepatitis despite the 
non-randomised allocation of corticosteroid therapy and the liberty of 
clinicians to discontinue corticosteroids in the event of ‘non-response’ after 
seven days of treatment. This implies that these measures are clinically 
robust and applicable in practice as well within the restrictions of a clinical 
trial. The inclusion of patients on clinical criteria without the need for biopsy 
might raise concern that some patients without histological alcoholic hepatitis 
might have been included in the study. This is possible, however the clinical 
criteria used are in keeping with those proposed for clinical trials32 and biopsy 
is infrequently used to diagnose alcoholic hepatitis in the United Kingdom33. 
Therefore the inclusion criteria are reflective of current standard practice. 
Whilst the mGAHS may be criticised for being a categorical score, even 
continuous scores such as the DF and MELD require a threshold to be 
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defined to guide clinical management. Therefore, categorisation is inevitable if 
a score is to be clinically applied. The current study indicates the 
effectiveness and robustness of the mGAHS and NLR in both clinical practice 
and clinical research. 
This study indicates that for some alcoholic hepatitis patients there are 
characteristics evident before corticosteroid treatment that could be used to 
avoid a trial of therapy to assess response. Whilst further validation in other 
patient cohorts is justified, this analysis from the STOPAH cohort with 
subsequent validation shows that mGAHS and NLR could help stratify risk 
and likelihood of corticosteroid response in patients with alcoholic hepatitis. 
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Table 1: Characteristics of the patients studied from the STOPAH Cohort and 
the Validation Group. Characteristics of those patients from STOPAH not 













































































GAHS≥9 47% 49% 42% 
MELD≥21 84% 84% 83% 
Lille≥0.45 45%* 51%* 40% 
 
WCC: Total White Blood Cell Count 
GAHS: Glasgow Alcoholic Hepatitis Score 
MELD: Model of End-Stage Liver Disease 
DF: Discriminant Function 
INR: International Normalised Ratio 
Mean values shown; in parentheses: 95% Confidence Intervals or percentage 
of available data 








Table 2: Association of Neutrophil-to-Lymphocyte ratio (NLR) with Acute 
Kidney Injury (AKI) (incident and at baseline) and presence of Infection at 
baseline and the development of incident infection (7 and 28 days after 
randomisation).  
 Baseline NLR 
Baseline AKI Present 
n=63 
11.12 
(8.64, 13.59) p=0.0001 




Incident AKI Present 
n=67 
7.53 
(6.37, 8.69) p=0.0056 









(6.60, 9.08) p=0.021 










(6.30, 9.20) p=0.035 










(6.29, 7.99) p=0.025 




Mean values shown; in parentheses: 95% Confidence Intervals 
 




Table 3: Integration of Neutrophil-to-Lymphocyte ratio (NLR)  in to Glasgow 
Alcoholic Hepatitis Score (GAHS) to create the modified GAHS (mGAHS): 
mGAHS Score Given 
Variable 1 2 3 
Bilirubin (µmol/l) <125 125-250 >250 
Prothrombin Time ratio/ INR <1.5 1.5-2.0 >2.0 
Blood Urea (mmol/l) <5.0 ≥5.0  
Age <50 ≥50 
Neutrophil-Lymphocyte ratio (NLR) <5.0 ≥5.0 
 









Table 4: Day 90 Mortality by Neutrophil-to-Lymphocyte ratio (NLR) Category 
and modified Glasgow Alcoholic Hepatitis Score (mGAHS) Category in 
STOPAH patients 
 NLR<5 NLR 5-8 NLR>8 
Prednisolone Untreated Treated Untreated Treated Untreated Treated 
mGAHS<9 
n=325 













HR 0.58 (0.34, 1.00) 
P=0-822 
 
HR: Hazard Ratio 




Table 5: Mortality Relative to Neutrophil-to-Lymphocyte ratio (NLR) Category, 
modified Glasgow Alcoholic Hepatitis Score (mGAHS) Category and 
Prednisolone Treatment in all patients in the Validation Cohort.  
  NLR<5 NLR 5-8 NLR>8 






































































HR 0.48 (0.20, 1.14) 
P=0.362 
 
HR: Hazard Ratio 
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Table 6: Comparison of Treatment Strategies derived from the STOPAH 
patient group. 
DF/Lille Strategy: all patients with DF≥32 treated with prednisolone with Lille 
Response assessed at Day 7 
GAHS/Lille Strategy: only patients with GAHS≥9 treated with prednisolone with Lille 
Response assessed at Day 7 
MELD/Lille Strategy: only patients with MELD≥21 treated with prednisolone with Lille 
Response assessed at Day 7 
NLR Strategy: NLR<5 and NLR>8 not treated; NLR 5-8 treated with prednisolone 
                                    DF/Lille Strategy 
 Proportion 28-Day Infection 90-Day Mortality 
No Prednisolone 0% - - 
Prednisolone: Lille (+) 60% 22.6% 15.1% 
Prednisolone Lille (-) 40% 56.1% 41.8% 
TOTAL 100% 36.1% 25.9% 
GAHS/Lille Strategy 
 Proportion 28-Day Infection 90-Day Mortality 
No Prednisolone (GAHS<9) 53% 24.3% 15.0% 
Prednisolone (GAHS≥9): Lille (+) 22% 25.4% 22.3% 
Prednisolone (GAHS≥9): Lille (-) 25% 48.6% 47.3% 
TOTAL 100% 29.6% 24.7% 
MELD/Lille Strategy 
 Proportion 28-Day Infection 90-Day Mortality 
No Prednisolone (MELD<21) 16% 10% 8.5% 
Prednisolone (MELD≥21): Lille (+) 47% 21.7% 17.5% 
Prednisolone (MELD≥21): Lille (-) 37% 44.1% 43.0% 
TOTAL 100% 30.5% 25.5% 
NLR Strategy 
 Proportion 28-Day Infection 90-Day Mortality 
No Prednisolone (NLR<5)) 47% 22.5% 13.2% 
No Prednisolone (NLR>8)) 25% 23.8% 37.6% 
Prednisolone (NLR 5-8) 28% 20.9% 21.0% 
TOTAL 100% 22.4% 21.5% 
 
MELD: Model of End-Stage Liver Disease 
DF: Discriminant Function 
Glasgow Alcoholic Hepatitis Score (GAHS) 
Neutrophil-to-Lymphocyte ratio (NLR) 
Lille (+): Lille Responder 
Lille (-): Lille Non-Responder 

















































Figure 1: Survival Curves Assessing Effect of Prednisolone using Baseline 













Figure 2: Effect of Prednisolone Relative to Neutrophil-to-Lymphocyte ratio 
(NLR) Category. Differences between marked columns noted. 
A) Chance of Lille Response 
B) Chance of 25% Fall in Bilirubin by Day 7 
C) Development of Infection by Day 7 
D) Development of Infection by Day 28 
E) Development of Incident Acute Kidney Injury (AKI) 





































*p=0.01; OR 1.86 (1.16, 2.99) A 




* p=0.006; OR 2.60 (1.32, 5.14) 


















































* p=0.031; OR 1.76 (1.05, 2.96) 
* 
* 
#p=0.005; OR 2.72 (1.35, 5.47) 





*p=0.012: HR: 1.93 (1.17, 3.19) 
* 
* 









































Figure 3: Area under the Receiver Operating Curve for MELD, GAHS, DF and 
mGAHS and CLIF-OF Scores 
 
 28-Day Outcome 90-Day Outcome 
mGAHS 0.783 (0.752, 0.812) 0.738 (0.705, 0.769) 
DF 0.683 (0.649, 0.717) 0.690 (0.655, 0.723) 
GAHS 0.762 (0.730, 0.792) 0.719(0.686, 0.751) 
MELD 0.738 (0.705, 0.769) 0.718 (0.684, 0.750) 
CLIF-OF Score 0.730 (0.697, 0.762) 0.680 (0.645, 0.713) 
 
95% Confidence Intervals in parentheses 
MELD: Model of End-Stage Liver Disease 
DF: Discriminant Function 
Glasgow Alcoholic Hepatitis Score: GAHS 
Neutrophil-to-Lymphocyte ratio: NLR 
Modified Glasgow Alcoholic Hepatitis Score: mGAHS 
Chronic Liver Failure- Organ Failure: CLIF-OF 
   




Supplementary Tables and Figures: 
Supplementary Table 1: Differences in Patient Characteristics between 












































































WCC: Total White Blood Cell Count 
GAHS: Glasgow Alcoholic Hepatitis Score 
MELD: Model of End-Stage Liver Disease 
DF: Discriminant Function 
INR: International Normalised Ratio 
 
Mean values shown; in parentheses: 95% Confidence Intervals or percentage 
of available data 








Supplementary Table 2: Mortality Relative to Neutrophil-to-Lymphocyte ratio 
(NLR) Category and Prednisolone Treatment in all patients (A) and with 
exclusion of those patients presenting with Infection or Gastro-intestinal 
Bleeding (B) in the STOPAH Cohort. 
A) All Patients 















8.2% 5.8% 25.7% 5.7% 29.7% 30.6% 
P = 0.359 
 
P=0.0001 





13.2% 19.0% 34.5% 21.0% 37.6% 41.8% 
P = 0.176 
 
P=0.012 
HR 0.52 (0.31, 0.86) 
P=0-604 
 
B) Excluding Patients Presenting with Infection or GI Bleeding 















7.5% 5.0% 26.5% 2.3% 30% 31% 
P = 0.349 
 
P<0.0001 

















Supplementary Table 3: Comparison of Cut Offs for A) MELD, B) GAHS, C) 
mGAHS 
A) MELD 
 Cut Off Sensitivity Specificity +LR 95% CI -LR 95% CI 
28-Day 
Outcome ≥21 95.7 18.6 1.18 1.1 - 1.2 0.23 0.10 - 0.6 
90-Day 
Outcome ≥21 94.2 20.0 1.18 1.1 - 1.2 0.29 0.2 - 0.5 
 
B) GAHS 
 Cut Off Sensitivity Specificity +LR 95% CI -LR 95% CI 
28-Day 
Outcome ≥9 78.2 58.3 1.87 1.6 - 2.1 0.38 0.3 - 0.5 
90-Day 
Outcome ≥9 71.2 60.8 1.82 1.6 - 2.1 0.47 0.4 - 0.6 
 
C) mGAHS 
 Cut Off Sensitivity Specificity +LR 95% CI -LR 95% CI 
28-Day 
Outcome ≥9 88.2 46.7 1.66 1.5 - 1.8 0.25 0.2 - 0.4 
90-Day 
Outcome ≥9 82.3 49.4 1.63 1.5 - 1.8 0.36 0.3 - 0.5 
 
LR: Likelihood Ratio 
GAHS: Glasgow Alcoholic Hepatitis Score 
MELD: Model of End-Stage Liver Disease 








Supplementary Figure 1: Neutrophil-to-Lymphocyte ratio (NLR) and Acute-on-
Chronic Liver Failure (ACLF) Grade. Grades 2 and 3 merged on account of 






5.8 (5.4, 6.1)* 6.6 (5.7, 7.5)* 
9.4 (8.0, 10.7) 
*p<0.0001 compared with ACLF 2/3 








































p<0.0001 HR 3.91 (2.96, 5.17) 
 
Supplementary Figure 2: Survival Relative to the modified Glasgow Alcoholic 









mGAHS Survival (%) Total sample 
<9 290 (89.2%) 325 
>8 297 (64.6%) 460 
Overall 587 (74.8%) 785 




Supplementary Figure 3: Proportions of NLR Category Relative to Baseline 
Prognostic Score Category: mGAHS, GAHS and MELD. 
 
GAHS: Glasgow Alcoholic Hepatitis Score 
MELD: Model of End-Stage Liver Disease 
mGAHS: modified Glasgow Alcoholic Hepatitis Score 
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